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AbstrACt
Objective To determine which service models and 
organisational structures are effective and cost-effective 
for delivering tuberculosis (TB) services to hard-to-reach 
populations.
Design Embase and MEDLINE (1990–2017) were 
searched in order to update and extend the 2011 
systematic review commissioned by National Institute 
for Health and Care Excellence (NICE), discussing 
interventions targeting service models and organisational 
structures for the identification and management of TB 
in hard-to-reach populations. The NICE and Cochrane 
Collaboration standards were followed.
setting European Union, European Economic Area, 
European Union candidate countries and Organisation for 
Economic Co-operation and Development countries.
Participants Hard-to-reach populations, including 
migrants, homeless people, drug users, prisoners, sex 
workers, people living with HIV and children within 
vulnerable and hard-to-reach populations.
Primary and secondary outcome 
measures Effectiveness and cost-effectiveness of the 
interventions.
results From the 19 720 citations found, five new studies 
were identified, in addition to the six discussed in the 
NICE review. Community health workers from the same 
migrant community, street teams and peers improved 
TB screening uptake by providing health education, 
promoting TB screening and organising contact tracing. 
Mobile TB clinics, specialised TB clinics and improved 
cooperation between healthcare services can be effective 
at identifying and treating active TB cases and are likely 
to be cost-effective. No difference in treatment outcome 
was detected when directly observed therapy was 
delivered at a health clinic or at a convenient location in 
the community.
Conclusions Although evidence is limited due to the 
lack of high-quality studies, interventions using peers and 
community health workers, mobile TB services, specialised 
TB clinics and improved cooperation between health 
services can be effective to control TB in hard-to-reach 
populations. Future studies should evaluate the (cost-)
effectiveness of interventions on TB identification and 
management in hard-to-reach populations and countries 
should be urged to publish the outcomes of their TB 
control systems.
PrOsPErO registration number CRD42015017865.
IntrODuCtIOn 
Prevention and control of tuberculosis (TB) 
is based on early detection and diagnosis of 
strengths and limitations of this study
 ► Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses and Cochrane Collaboration 
reporting guidelines for systematic reviews were 
followed.
 ► The search was highly sensitive, but we might have 
missed important information as many European 
countries do not publish their tuberculosis identifi-
cation and management data in journals; our search 
focused on Embase and MEDLINE.
 ► We identified five studies and discuss the results to-
gether with the six studies identified by the National 
Institute for Health and Care Excellence review to 
give the complete body of evidence.
 ► None of the included studies was of high quality, 
and there was high heterogeneity across the studies 
prohibiting a meta-analysis.
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TB followed by effective treatment. In 2015, there were 
an estimated 10.4 million incident TB cases worldwide, an 
estimated 4.3 million cases were either not diagnosed or 
diagnosed but not reported to national TB programmes.1 
Trends for TB treatment are encouraging, with most noti-
fied TB cases completing their treatment successfully, 
although treatment success rates in some regions, such as 
the European region, were considerably below the WHO 
World Health Assembly target of 85%.1 
In many countries with a low TB incidence (less than 10 
TB cases per 100 000 population),2 TB prevails in the big 
cities where vulnerable and hard-to-reach (underserved) 
populations are concentrated.3 These populations, such 
as people who are homeless (or have insecure accom-
modation), misuse drugs or are migrants, are at higher 
risk of contracting TB and are more likely unable or 
unwilling to seek medical care and comply with the long-
term TB treatment. Managing TB in those populations is 
therefore challenging, due to barriers caused by stigma, 
cultural barriers, poor access to healthcare services and 
low levels of accurate TB knowledge.4–7 This therefore 
requires special efforts. Healthcare services need to be 
organised effectively to identify and diagnose TB cases 
and to provide adequate treatment and support. This 
can be organised in different ways, for example, mainly 
as hospital based8 or health centre based,9 including the 
public sector, private sector,10 or civil society and other 
partners.11 Sometimes, organisation of the services has 
proven ineffective in managing TB.12
The review question of this systematic review with a 
scoping component was: ‘Which service models and 
organisational structures, including different types of 
healthcare workers and settings, are effective and cost-ef-
fective for delivering TB services to hard-to-reach popula-
tions in low- and medium-incidence countries?’.
Findings of this review and the previously published 
review series4 13 formed the base for the guidance docu-
ment by the European Centre for Disease Prevention and 
Control (ECDC) on controlling TB in hard-to-reach and 
vulnerable populations.14
MEthODs
In 2011, the Matrix Knowledge Group published a review, 
commissioned by the National Institute for Health and 
Clinical Excellence (NICE), on effectiveness and cost-ef-
fectiveness of service models or structures, focusing on 
the type of healthcare worker and setting, to identify and 
manage TB in hard-to-reach populations. We updated 
and extended the NICE review15 using the same meth-
odology but adjusting the focus by excluding latent TB 
infection and including additional hard-to-reach popu-
lations. The review was conducted following standards 
described by the Cochrane Collaboration16 and NICE 
methods guidelines.17 Results are reported according 
to Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines.18 The review 
protocol was registered in advance in the database of 
prospectively registered systematic reviews in health and 
social care, PROSPERO (CRD42015017865).
selection of studies and data management
The same search strategy as for the previous NICE review15 
and the previous published review by Heuvelings et al13 
was used, searching Embase and MEDLINE through the 
Ovid platform. The search was expanded by including all 
European Union (EU)/European Economic Area and 
EU candidate countries to the Organisation for Economic 
Co-operation and Development countries (see box 1).15 
Two hard-to-reach populations (people living with HIV 
and children within vulnerable and hard-to-reach popula-
tions) were added in addition to the hard-to-reach popu-
lations included by the NICE review (migrants including 
refugees, asylum seekers and the Roma population, home-
less people including rough sleepers and shelter users, 
drug users, prisoners and sex workers).15 The update of 
the search conducted for the NICE review15 covered the 
period 1 January 2010 (overlapping the end of the search 
period of the NICE review15 with a few months) to 24 
box 1 Inclusion/exclusion criteria for this review
Inclusion criteria
 ► Discussing service models and organisational structures, different 
types of healthcare workers and settings for delivering TB services 
to hard-to-reach populations.
 ► Having been conducted in any of the EU/EEA countries (only updat-
ed review), the candidate countries* (only updated review) and the 
other OECD countries.†
 ► Having been published in 2010 or later for the OECD countries.†
 ► Having been published in 1990 or later for the EU/EEA countries and 
the EU candidate countries* not being one of the OECD countries 
(only updated review).
 ► Including data from any hard-to-reach population:
 – Homeless people.
 – People who abuse drugs or alcohol.
 – Sex workers.
 – Prisoners or people with a history of imprisonment.
 – Migrants, including vulnerable migrant populations such as asy-
lum seekers, refugees and the Roma population.
 – Children within vulnerable and hard-to-reach populations (only 
updated review).
 – People living with HIV (only updated review).
 ► Present quantitative empirical data.
 ► Being a (cost)-effectiveness study or any other type of quantitative 
primary research, discussing (cost-)effectiveness.
Exclusion criteria
 ► Latent TB infection (only updated review).
 ► Systematic review (only used for reference searching).
*EU candidate countries: Albania, Montenegro, Serbia, the former Yugoslav 
Republic of Macedonia and Turkey.
†OECD countries: Australia, Austria, Belgium, Canada, Chile, Czech Republic, 
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, 
Ireland, Israel, Italy, Japan, Korea, Luxembourg, Mexico, the Netherlands, New 
Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, 
Switzerland, Turkey, UK and USA.
EU, European Union; EEA, European Economic Area; OECD, Organisation for 
Economic Co-operation and Development; TB, tuberculosis.
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February 2017. The search for the expanded geograph-
ical area and newly included hard-to-reach populations 
covered a time period from 1 January 1990 (beginning 
of the search period used in the NICE review15) to 24 
February 2017.
Reference lists of relevant systematic reviews were 
scanned. No language restrictions were applied.
Studies focusing on the effectiveness and/or cost-effec-
tiveness of interventions for service models and organ-
isational structures supporting TB identification and 
management of hard-to-reach populations (see box 1) 
were included.
Predefined interventions were using more convenient 
locations (like specialised TB centres, shelters for home-
less people or drug users, needle exchange/methadone 
programme locations, port of arrival, schools or mobile 
clinics) and peers or healthcare workers with the same 
ethnic or cultural background; however, other interven-
tions could also be included if they supported TB iden-
tification or management in hard-to-reach populations. 
TB identification tools, TB diagnostics, incentives, social 
support, directly observed therapy and treatment of 
comorbidities are discussed in another review.13 In this 
review, we aim to identify the effectiveness of the type of 
health worker and setting to identify and manage TB in 
hard-to-reach and vulnerable populations.
The comparator was defined during the review process; 
interventions were compared with a relevant comparator, 
for example, usual care or no intervention, another inter-
vention or historical comparison.
Outcomes were defined as any measure of TB identifi-
cation and management (eg, number of people screened, 
screening coverage, proportion receiving treatment and 
treatment completion rate). Effectiveness was defined 
as an improvement in any measure of TB identification 
and/or management. Randomised and non-randomised 
studies were eligible for inclusion.
See online supplementary material I for the PROS-
PERO study protocol, online supplementary material II 
for Population-Intervention-Comparator-Outcome-Study 
design) questions and online supplementary material III 
for the complete search strategy and search results.
Data extraction, data items and synthesis
Identified citations were entered into an EndNote data-
base, and duplicates were removed (EndNote X7.1, 
Thomson Reuters 2014). The inclusion criteria were 
piloted and refined using the first 25 citations. Double 
screening was conducted by one reviewer screening 
100% of the citations (CCH), while another two reviewers 
screened 50% of the citations each (PFG and SGdV) 
for inclusion on title and abstract. Disagreement was 
resolved by discussion. Full-text files of included citations 
were retrieved; irretrievable articles (not available after 
attempts online, from the university library or through 
contacting authors) were excluded. Two reviewers 
assessed full-text records for inclusion (CCH and PFG). 
Disagreement was resolved by discussion. Agreement 
after screening on title and abstract was 99.6% with an 
inter-rater reliability (Cohen’s kappa) of κ=0.985.
Data extraction forms from the NICE review15 were 
used to extract information on participant characteristics, 
settings, types of services/organisational structures, types 
of healthcare workers delivering the service, outcome 
measures, methods of analysis and results. For one study, 
data extraction was conducted by two reviewers (CCH and 
PFG) independently. For the remaining studies, data 
extraction was conducted by one reviewer (CCH) and 
checked by a second (PFG); disagreement was resolved 
by discussion. In one case, the study author was contacted 
to verify data and obtain additional data.19
To facilitate comparability, data synthesis was structured 
in a similar way to that of the NICE review.15 Studies were 
divided into those examining service models and organi-
sational structures for TB identification (screening) and 
those examining service models and organisational struc-
tures for TB management (treatment and support) in 
hard-to-reach populations. Data were analysed narratively, 
and appropriateness of meta-analysis was considered. 
Findings were reported as stated by the study authors.
risk of bias in individual studies and overall strength of 
evidence
The modified NICE Quality Assessment Tools17 (based on 
the Graphical Appraisal Tool for Epidemiological studies) 
were used to assess quality and risk of bias of included 
studies. This included an assessment of selection of study 
sample, minimisation of selection bias and contami-
nation, controlling confounding, outcome measure-
ments, analytical methods and risk of bias. Two reviewers 
(CCH and PFG) assessed one study independently; the 
remaining studies were assessed by one reviewer (CCH) 
and checked by a second reviewer (PFG). Any disagree-
ment was resolved by discussion. Studies were given 
a quality rating based on the quality assessment: high 
quality [++], medium quality [+] or low quality [−]. The 
strength of the evidence was assessed and reported as 
described in the previous NICE review15 (online supple-
mentary material IV).
Patient and public involvement statement
Patient and public were not involved in the design of this 
systematic review.
rEsults
Of the 19 720 citations identified by the literature search 
five studies were included in this review (figure 1).11 19–22 
These five studies are in addition to the six studies23–28 
included in the NICE review.15 The results section in 
this paper focuses on the evidence of the five studies 
identified in our updated review. The evidence state-
ments (presented in online supplementary material IV) 
summarise evidence identified in terms of consistency, 
quality and applicability, combining evidence from the 
NICE review15 and this update.
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All five studies were conducted in the EU; two in the 
UK,19 22 one in Germany,20 one in Portugal11 and one 
in Spain.21 Two studies focused on homeless people,19 20 
one on homeless people and drug users,22 one on drug 
users alone11 and one on migrants.21 Four studies5 19–21 
addressed the influence of the type of healthcare worker 
on TB identification and TB management and one study 
focused on the influence of different settings on TB iden-
tification.22 A variety of study designs were included: one 
study was a prospective cluster randomised controlled 
trial (RCT),19 one was an economic evaluation using a 
compartmental model of treated and untreated active 
TB cases22 and three studies were retrospective compar-
ison studies.11 20 21 Study characteristics of included 
studies are described in table 1. The data extraction 
forms by study are presented in online supplementary 
material V.
None of the included studies in this review had a low 
risk of bias, three studies19 21 22 had a medium risk of 
bias and the other two studies5 20 were assessed as having 
a high risk of bias (online supplementary material VI).
We did not perform a meta-analysis due to study hetero-
geneity. Results were synthesised narratively.29
Main outcomes for services structures and organisa-
tional models for TB identification among hard-to-reach 
populations, combined with the findings of the NICE 
review,15 are summarised in table 2. For full evidence 
statements, see online supplementary material IV.
Figure 1 Study selection process.
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Three studies19–21 compared the effect of the type of 
healthcare worker on TB identification.
In the UK, a cluster randomised trial found that 
peer educators working together with shelter staff to 
encourage homeless people to participate in a TB 
screening programme using mobile X-ray units did not 
improve screening uptake compared with encourage-
ment by shelter staff only (respectively 40%, IQR 25–61 
vs 45%, IQR 33–55; adjusted risk ratio 0.98, 95% CI 0.80 
to 1.20).19 Control sites were not ‘naïve’ for peer inter-
vention, which could have caused contamination of the 
control sites and contributed to the negative finding.
In Germany, introduction of TB education and promo-
tion of voluntary chest X-ray screening at least once every 
2 years by community health workers (CHWs) improved 
screening uptake in homeless people and drug users. 
Annual screening coverage increased from 10.0% at the 
beginning of the study period (2002–2004) to 15.0% 
during the middle part of the study period (2004–2006); 
the last part of the study period had a 13.4% annual 
screening coverage (2005–2007). Screening once every 
2 years increased screening coverage from 18.0% (2002–
2004) to 26.4% (2004–2006). Coverage was 23.4% at the 
third and final study period (spanning 2005–2007).20 
The authors did not test for statistical significance, and 
denominator data (the number of homeless people and 
drug users in the study area) were estimated.
In Barcelona, Spain, contact tracing organised by 
CHWs coming from the same migrant community as 
the person diagnosed with TB improved contact tracing 
among migrants to 66.2% (2003–2005) compared with 
55.4% (2000–2002) in the period before the implementa-
tion of the intervention using CHWs (adjusted OR of an 
index case having their contacts screened before and after 
the intervention was 1.8, 95% CI 1.3 to 2.5, p<0.001).21 
Identification and tracing of at least one contact was 
taken as appropriate contact tracing, where all contacts 
at risk should be traced to detect and treat TB transmis-
sion early. The population characteristics varied, and the 
age and country of origin were different between both 
periods. The importance of contact tracing is to identify 
cases early to reduce transmission; the authors did not 
report if any of the contacts traced had active TB.
Two studies11 22 evaluated the effect of the type of 
healthcare worker and the setting on TB identification 
and TB management.
In Portugal, improved cooperation of ‘key partners’ 
(street teams, TB clinics, drug user support centres, local 
public health department and local hospital) for TB iden-
tification and management in drug users was evaluated 
in a before-and-after study. Representatives of all ‘key 
partners’ (authors’ term) worked on improving policies, 
clinic screening procedures and cooperation. Key part-
ners were trained in identifying drug users in their popu-
lation, and offering health promotion, notification cards, 
free transport to the TB clinic, free medical and substance 
abuse care, directly observed therapy (DOT) for active 
TB cases, identification of non-compliant patients and F
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the cause of non-compliance and tailor-made strategies 
to improve compliance. This resulted in an increase of 
TB screening uptake, from 52 drug users being screened 
before the intervention (2001–2003 when there was 
no active screening policy) to 465 drug users screened 
thereafter (2005–2007). Of all people misusing drugs 
taking up screening, the proportion without TB symptoms 
increased from 41.6% to 93.5% (OR=21.76; 95% CI 13.03 
to 36.33) indicating improved TB awareness and access 
to screening facilities for drug users. Of all drug users 
with active TB, the proportion identified by screening 
increased from 13.4% to 61.0% (OR 10·1; 95% CI 4.44 
to 23.0). Treatment default rates decreased from 35.4% 
to 10.2% (OR 0.21, 95% CI 0.08 to 0.54), compared with 
the period before the intervention (2001–2003) when 
TB treatment was not compulsory and compliance was 
stimulated by TB education and providing information 
on the importance of treatment completion.11 Although 
the absolute number of drug users screened increased, 
information on the screening coverage was not available 
as denominator data were not provided. Another limita-
tion is that the results were not adjusted for confounding 
factors, baseline characteristics might have been different 
as the two cohorts were recruited over different time 
periods and participation was voluntary which may have 
led to selection bias.
In the UK, the effectiveness and cost-effectiveness of 
the ‘Find and Treat’ service (raising awareness of TB 
screening and providing a mobile TB screening and 
treatment service) for homeless people and drug users 
was evaluated and compared with people (with a history 
of homelessness, imprisonment, drug abuse or mental 
health problems) self-presenting to a London TB clinic 
receiving standard TB care at the clinic.22 The authors 
estimated that 22.9% of the patients detected by the ‘Find 
and Treat’ service with the longest first symptom-to-detec-
tion time would not have self-presented plus 35.4% were 
asymptomatic at time of detection and would not have 
self-presented, only part of the asymptomatic patients 
would self-present to a TB clinic at a later stage when 
symptoms would have developed. The ‘Find and Treat’ 
service had a higher treatment completion rate (67.1% 
vs 56.8%) and a lower lost to follow-up rate (2.1% vs 
17.2%) compared with the control group receiving stan-
dard TB care at a TB clinic. The authors concluded that 
the ‘Find and Treat’ service was cost-effective when using 
the threshold used by NICE of £20 000 to £30 000/QALY 
gained, with an incremental cost ratio of £18 000 per 
QALY gained for the TB screening service and £4100 per 
QALY gained for the TB management service. This study 
has a few limitations: first, it is a non-randomised study, 
second, the ‘Find and Treat’ service identifies extremely 
hard-to-reach populations of which some would never 
self-present, therefore the findings could be even better 
in less hard-to-reach populations, and third, the econom-
ical evaluation is based on a compartmental model that 
does not take secondary transmission and drug resistance 
into account.
DIsCussIOn
To tackle TB and disrupt transmission in high-income, 
low TB incidence settings, improvement of TB care in 
hard-to-reach populations is of vital importance. In this 
updated review, five studies,11 19–22 published between 
1 January 2010 and 24 February 2017, evaluating effec-
tiveness of services models and organisational structures 
supporting TB identification and management of hard-
to-reach populations, were identified in addition to the 
six studies considering active TB23–28 identified by the 
NICE review.15 Only one study22 evaluated cost-effective-
ness. Although the evidence from two reviews is limited, 
it highlights those interventions that are likely to be effec-
tive and those that have no clear evidence of being effec-
tive (table 2). For development of the ECDC guidance 
document,14 a scientific panel compiled by ECDC care-
fully considered these findings. Their main suggestions 
for action were to involve CHWs or peers to improve TB 
screening uptake and TB treatment completion among 
homeless people20 and drug users5 20 23; to use outreach 
teams to improve TB screening uptake and TB treatment 
completion among vulnerable populations22; and to 
strengthen relationships and good collaboration between 
healthcare workers, peers, communities and patients to 
improve treatment outcome among vulnerable popu-
lations.5 20 22 23 The updated systematic review provided 
evidence for all suggestions except for using peers to 
improve screening uptake. This is in contrast to an Amer-
ican study23 included in the original NICE review,15 which 
showed that peers improved contact tracing and treat-
ment adherence among drug users.
strengths and limitations
PRISMA and Cochrane Collaboration reporting guide-
lines for systematic reviews were followed. Established 
screening protocols were used, including double 
screening, and the search was highly sensitive. The meth-
odology from the previous NICE review15 was followed, 
in order to connect this update and, so, describe the 
full body of relevant evidence. High-quality evidence is 
lacking. Only one23 study from the NICE review15 was 
considered to be of high quality; all other studies had 
some risk of bias (five medium risk19 21 22 24 26 and five 
high risk11 20 25 27 28). Therefore, only limited conclusions 
can be drawn. Most studies lacked identification and 
adjustment for confounding factors and the use of appro-
priate analytical methods. In addition, many studies were 
biased, particularly with regard to potential selection 
bias. A meta-analysis could not be performed because of 
heterogeneity across the studies. Gaps in evidence exist; 
no studies focusing on children within vulnerable and 
hard-to-reach populations or on people living with HIV or 
sex workers were identified. Only three studies provided 
economic data; one study identified by this review22 and 
two studies25 27 by the NICE review.15
Our search focused on publications in databases 
Embase and MEDLINE. Many European countries have 
strong organisational structures for TB identification and 
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management, but these countries did not publish their 
data on these organisational structures in journals, which 
may have caused a publication bias. Comparing findings 
of the NICE review15 with this review comes with some 
limitations. For the NICE review, only 10% of the citations 
were double screened,15compared with 100% for this 
updated review; therefore, studies conducted between 
1990 and 2010 might have been missed. The NICE review 
focused their recommendations on the population in the 
UK,15 and this review focused on populations in high-in-
come, low TB incidence countries. Further methodology 
was identical.
The evidence identified by this review and the previous 
NICE review15 along with evidence presented in a review 
series covering the barriers and facilitators of seeking TB 
care,6 and the effectiveness of interventions for TB identi-
fication and management in hard-to-reach populations,13 
was used to develop the ECDC guidance on improving 
TB identification and management among hard-to-
reach and vulnerable populations in Europe.14 ECDC 
recommended that implementation of the interven-
tions is context specific; it depends on the setting, target 
population, resources available and healthcare systems 
in place. Interventions focusing on one specific hard-
to-reach population might not work in another hard-to-
reach population; therefore, the interventions have to be 
adapted and reassessed per target population.14 Given the 
scope of this review, considering settings across Europe, 
findings presented here are potentially relevant to any 
low incidence region and are relevant to other institu-
tions/governmental organisations seeking to improve 
service structures for TB identification and management 
among hard-to-reach populations.
Characteristics of different hard-to-reach populations 
and their TB epidemiology vary per country and setting. 
Challenges in identification and management of TB 
should be identified and targeted, tailored to the specific 
setting and hard-to-reach population. These TB interven-
tions could be integrated within broader programmes 
targeting specific populations. A follow-up systematic 
review should include information from national public 
health services about their organisational structures for 
TB identification and management. National public 
health services are urged to regularly analyse their organi-
sational structures for TB identification and management 
and publish these data.
Efforts to improve quality of research on service models 
and organisational structures should be made, even 
though it is often challenging to perform ‘clean’, unbi-
ased and unconfounded trials in hard-to-reach popula-
tions, as attrition rates are often high, and confounding 
factors are plentiful. This includes conducting (cluster) 
RCTs and before-and-after studies where appropriate, 
recruiting an adequate number of participants, using 
relevant control groups and minimising selection bias. 
Standardised case definitions for hard-to-reach popu-
lations should be created. Feasibility, effectiveness, 
cost-effectiveness and impact of interventions should be 
evaluated. Mathematical economic models can be used 
to evaluate costs.14
COnClusIOns
Identification and management of TB in hard-to-reach 
populations is suboptimal.2 Therefore, service models 
and organisational structures to identify and manage TB 
in hard-to-reach populations should be improved and 
evaluated regularly.
Our systematic review, in conjunction with the original 
NICE review,15 provides limited evidence, due to the lack 
of high-quality studies, that interventions such as using 
peers and CHWs, mobile TB services, specialised TB 
clinics, screening or active case finding in non-health-
care settings, as well as improved cooperation between 
key services can help to improve TB identification and 
management.
Further research should be undertaken to evaluate 
other effective and cost-effective ways to identify and 
manage TB in hard-to-reach populations, and countries 
with good TB control systems are urged to evaluate their 
system and publish the data.
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